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Objective: To review the pharmacological properties and the available clinical data of full 
length parathyroid hormone (PTH) in post-menopausal osteoporosis.
Sources: A MEDLINE search was completed, together with a review of information obtained 
from the manufacturer and from the medicine regulatory agencies. 
Study and data selection: Studies were selected according to relevance and availability. 
Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, 
dosing, etc) was analyzed.
Results: Different studies have shown that, when administered intermittently as a subcutaneous 
injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral 
fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential 
treatment with alendronate is associated with a therapeutic beneﬁ  t in terms of increase in BMD. 
Further trials are necessary to determine long-term safety and the role of PTH in combination 
with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by 
an anti-catabolic agent. There are currently no completed comparative trials with other osteo-
porosis treatments. 
Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, 
appears to be a safe and efﬁ  cacious treatment option for high risk osteoporosis. More data are 
needed to determine its speciﬁ  c role in osteoporosis treatment.
Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
Introduction
Musculoskeletal diseases, mainly rheumatoid arthritis, osteoarthritis, and osteoporosis 
are associated among older people with a loss of independence and a need for additional 
support or admission to residential care. In the European Union (EU), more than 
15%–20% of medical consultations in primary care are related to musculoskeletal 
disease (ECHCPD 2006). Osteoporosis has been deﬁ  ned as “a skeletal disease 
characterized by compromised bone strength predisposing a person to an increased 
risk of fracture” (NIH 2001). The incidence and prevalence of osteoporosis is greater 
in females and increases with age. Future projections in the EU (15 members) show 
an increase in the annual number of hip fractures from 414 thousand in 2000 to 972 
thousand by 2050. Over the same period, the prevalence of vertebral fractures would rise 
from 23.7 million to 37.3 million (ECHCPD 2006). More than 1.5 million Americans 
suffer osteoporotic fractures every year (half of them are vertebral fractures) with an 
annual cost of nearly $14 billion to the US healthcare system (Riggs and Melton 1995; 
Ray et al 1997). By 2020, that ﬁ  gure is expected to increase to 14 million cases of 
osteoporosis and over 47 million cases of low bone mass (NOF 2002). This increase 
in cases could cause the number of hip fractures to double or triple by 2040 (Schneider 
and Guralnik 1990).Clinical Interventions in Aging 2007:2(1) 164
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Bone loss produces fewer and thinner bony spicules, also 
loss of horizontal bracing rods, which leads to unsupported 
vertebral trabeculae and further weakening of bone integrity 
(Rosen 2006). Many osteoporotic patients have lost more 
than 30% of their peak bone mass and continue to have frac-
tures after being treated with antiresorptive drugs. These an-
ticatabolic drugs (bisphosphonates, calcitonin, and selective 
estrogen receptor modulators) are capable in reducing bone 
markers and modestly increasing bone density to 8%–10% 
at three years (Riggs and Parﬁ  tt 2005).
Therefore, the availability of effective anabolic drugs 
that possess the potential to increase bone mass and reduce 
fracture risk dramatically has meant the onset of a new era 
in osteoporosis therapy.
The anabolic activity of the parathyroid hormone (PTH) 
(1–84) and the N-terminal fragment and/or analogues of 
PTH have been investigated for many years. Parathyroid 
hormone increases trabecular bone density by stimulating 
bone formation (Dempster et al 1993; Morley et al 1997). 
Markers of bone formation and resorption increase during 
PTH treatment (Hodsman et al 1993), and vertebral bone 
density increases markedly. (Hodsman et al 1997).
Historical perspective
Parathyroid glands were discovered in the late 19th century. 
The discussion about their function lasted until the ﬁ  rst quar-
ter of the 20th century as reviewed by Boothby in 1921. The 
death from tetany caused in animals by the removal of all of 
the parathyroid glands and their separate function from that of 
the thyroid were already known in 1891 (Gley 1891) . Fifteen 
years later, Erdheim (1906) showed the lack of parathyroid 
tissue in patients dying from postoperative tetany after thy-
roid surgery. Not without controversy, MacCallum proposed 
that the function of the parathyroid glands was the control of 
blood calcium (MacCallum and Voegtlin 1908), which was 
ﬁ  nally shown in 1925 by Collip (1925). Another 35 years 
were needed to purify and characterize the active principle 
of the glands (Aurbach 1959). As early as 1929, Albright and 
colleagues (Bauer et al 1929) and later Selye (1932) observed 
that PTH, in fact yet a “peptide extract”, could also be anabolic 
to the skeleton, producing increases in bone tissue in animals. 
Hence, not surprisingly, the ﬁ  rst clinical trial of PTH (1–34) 
for osteoporosis in humans was conducted in 1976 (Reeve et al 
1976). However, animal studies showing that the net effect on 
bone mineral density (BMD) depends on the balance between 
anabolic and catabolic actions on bone and that this balance 
is determined by the regimen of administration, appeared six 
years later (Tam et al 1982; Podbesek et al 1983).
Parathyroid hormone physiology
Parathyroid hormone, together with 1, 25-dihydroxyvitamin D, 
are the two major hormones modulating calcium and phosphate 
homeostasis. PTH is most responsible for maintaining 
serum-ionized calcium concentrations within a narrow 
range through its actions in the kidney—to stimulate 
renal tubular calcium reabsorption and the conversion of 
25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and 
thereby the calcium absorption and in the bone—to increase 
bone turnover (Brown et al 1995; Potts and Juppner 1996). 
PTH acts in bone to increase the number and activity of 
osteoblasts and osteoclasts, and increases bone turnover. 
With sustained elevations in PTH, osteoclastic activity could 
exceed that of osteoblasts, which results in a net release of 
calcium from bone and a decrease in BMD. On the contrary, 
single daily injections of PTH could increase osteoblastic 
activity preferentially, thereby increasing BMD and bone 
strength. (Tam et al 1982; Podbesek et al 1983).
The biological actions of PTH are mediated through binding 
to, at least, two distinct high afﬁ  nity cell-surface receptors 
speciﬁ  c for the N-terminal and C-terminal regions of the mol-
ecule, both of which are required for normal bone metabolism. 
The N-terminal portion of the molecule is primarily respon-
sible for the anabolic effects of intermittently administered 
PTH. These effects are mediated in the osteoblastic cells 
by multiple cellular pathways and involve the induction of 
several target genes as insulin-like growth factor-I (IGF-I), 
Runx2, amphiregulin 1, alpha hydroxylase, transform-
ing growth factor (TGF)-beta, RANKL, or mononuclear 
phagocyte colony-stimulating factor (M-CSF) (Rosen 2003). 
The consequence is the enhancement of the recruitment 
and activation of the osteoblasts increasing bone mass and 
bone strength. The C-terminal portion of the molecule has 
antiresorptive activity and is necessary for normal regula-
tion of N-terminal fragment activity: Several C-terminal 
fragments of PTH, derived both by direct secretion from the 
parathyroid glands and by postsecretory proteolysis of PTH, 
normally circulate in blood at concentrations several times 
higher than that of intact PTH. There is convincing evidence 
that parathyroid gland secretion of PTH is stimulated by 
hypocalcemia, whereas secretion of C-terminal fragments 
is promoted by hypercalcemia. Certain C-terminal PTH 
fragments inhibit osteoclast formation and bone resorp-
tion via direct effects on cells of the hematopoietic lineage 
through C-terminal fragment receptors, suggesting the 
presence of a negative feedback loop aimed to restrain release 
of calcium from bone into blood when it is not needed. Thus, 
these C-terminal PTH receptors may protect the skeleton by Clinical Interventions in Aging 2007:2(1) 165
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limiting bone resorption and disbalance the equilibrium in 
favour of net bone formation (Murray et al 2005). Moreover, 
the C-terminal PTH receptors are extraordinarily common in 
osteocytes—the most abundant of bone cells—where they 
regulate gap-junctional communication and cell survival 
and communication (Divieti et al 2001). These facts could 
suggest a major role in the crucial mechanosensory function 
of the osteocyte network. On the other hand, the C-terminal 
PTH receptors do not recognize any sequences within PTH-
related peptide (PTHrp). This could provide target cells with 
a means to discriminate between PTH and PTHrp (Murray 
et al 2005). Nevertheless, the C terminal receptor for pTH 
is still not universally accepted therefore only the PTH1R 
receptor is considered speciﬁ  c.
Description of the drug
Recombinant human PTH (1–84) is obtained by recombinant 
DNA technology. PTH is produced as a fusion protein. Post-
translational processing involves the cleavage of the leader 
sequence, leaving the mature protein as a single-chain 84 
amino-acids polypeptide (9.4 kDa) whose sequence is identical 
to that of the full-length native endogenous human PTH. It has 
no disulﬁ  de bonds and no glycosylation sites. The approved 
dose in the EU is 100 μg administered as a daily subcutaneous 
injection in the abdomen for a duration of up to 2 years.
Preclinical studies
Pharmacology
The effects of PTH on BMD, strength, and architecture were 
assessed in two pivotal studies: one in rat and one in monkey 
(Mosekilde et al 1991; Ejersted et al 1993; Jerome et al 2001; 
Fox et al 2007). In rat, treatment with PTH for 12 months 
produced a dose-related gain in cortical and trabecular bone 
mass, associated with increased bone strength. In monkey, 
PTH treatment for 39 weeks increased bone formation 
markers to a greater extent than bone resorption markers; and, 
at the high doses employed, resulted in signiﬁ  cant increases in 
trabecular bone mass and increases in vertebral and femoral 
neck bone strength. There was a negative inotropic effect of 
PTH in vitro that is considered not clinically relevant. Con-
cerns over potential cardiovascular effects of PTH appear to 
be relevant only when PTH concentrations are sufﬁ  ciently 
high to produce a catabolic effect on bone.
Pharmacokinetics
Pharmacokinetics (PK) parameters were determined in rats, 
dogs, and monkeys in several studies. The lymphatic system 
does not play an important role in the uptake of PTH from 
a subcutaneous injection site. In dogs, absorption was much 
slower than in rats and the tmax was considered to be on aver-
age 1.5 h for both sexes. Studies performed with monkeys 
revealed that the absorption was slower than in rats, and 
tmax values ranged from 35 minutes to 1.5 h (average 50 
minutes) for both sexes (Shrader and Ragucci 2005; White 
and Ahmad 2005).
Toxicology
Repeat-dose toxicity studies were conducted in the rat, dog, and 
cynomolgus monkey. The sensitivity of the dog to PTH-induced 
hypercalcemia and subsequent renal damage precluded the use 
of this animal as a non-rodent species. Carcinogenicity studies 
in rats receiving near lifetime daily injections showed dose de-
pendent exaggerated bone formation and an increased incidence 
of bone tumors, including osteosarcoma. Due to the differences 
in bone physiology in rats and humans, the clinical relevance of 
these ﬁ  ndings is minor. A 2-year study demonstrated no increase 
in osteosarcoma risk in rats treated with low-dose PTH (1–84) 
when compared with controls. Nevertheless, although osteosar-
comas have not been observed in clinical trials, it is recommended 
in that the treatment time does not exceed 24 months. PTH is not 
recommended during pregnancy.
Clinical studies
Pharmacology
The subcutaneous administration of 100 μg of PTH into the 
abdomen produces a rapid increase in plasma PTH levels 
that peaks at 1 to 2 hours after dosing with an average 
half life of about 1.5 hours. The absolute bioavailability of 
100 μg of PTH after subcutaneous administration in the 
abdomen is 55%. PTH absorption was slightly slower from 
the thigh than from the abdomen resulting in a plasma PTH 
proﬁ  le that has a lower peak level and longer duration with 
a greater increase in predosing levels and a higher incidence 
of patients with values above the upper limit of normal. The 
clearance of PTH is primarily hepatic and, in a lesser extent, 
renal (Martin et al 1976). A great within-subject variability 
was observed for maximal concentration and for the area 
under the 24-hours curve; nevertheless, the variability is 
reduced at the recommended dose and when administered 
in the abdomen. No adjustment is necessary in patients with 
mild to moderate renal impairment (creatinine clearance >30 
ml/min) or mild to moderate hepatic impairment (Child-Pugh 
scale 7–9 points). No differences in PTH pharmacokinetics 
were detected with regard to age or race. No interaction with 
other medicinal products seems to be probable (Shrader and 
Ragucci 2005; White and Ahmad 2005). Clinical Interventions in Aging 2007:2(1) 166
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Clinical efﬁ  cacy 
The clinical development of PTH in the treatment of post-
menopausal osteoporosis included one phase II dose ranging 
study, one pivotal phase III placebo-controlled study (TOP), 
an open-label extension study (OLES), and two phase III 
active control studies (PaTH, and POWER) (Table 1). 
Dose ranging study 
Hodsman and colleagues (2003) have published the results 
of a randomized, placebo-controlled, double blind, multi-
center, parallel-group dose response study. Postmenopausal 
women (aged 50 to 75 years) with osteoporosis (lumbar spine 
BMD 2.5 SD below the mean of healthy young women) 
were randomized to receive PTH 50 μg (n = 52), PTH 75 μg 
(n = 55), PTH 100 μg (n = 55)n or placebo (n = 55) during 
12 months. All the subjects received calcium (1000 to 
1500 mg/day) and vitamin D3 (400 IU/day). The primary 
objective was the change from baseline in lumbar spine BMD 
(L1-L4) with an intention-to-treat (ITT) approach. Lumbar 
spine BMD increased signiﬁ  cantly from the baseline in a time 
and dose-dependent fashion in all PTH groups but not in the 
placebo group (0.4% placebo; 1.6% 50 μg; 3.1% 75 μg; 4% 
100 μg). The 12-months results conﬁ  rmed the greater effect 
in the lumbar spine of the 100 μg dose (+7.8%) compared 
with the placebo (0.9%), 50 μg (3.1%), and 75 μg (4.9%) dose 
groups. BMD underestimated the anabolic effect of PTH in 
lumbar spine because bone area increased signiﬁ  cantly. A non-
signiﬁ  cant decrease (–0.9%) in total hip BMD occurred during 
the ﬁ  rst 6 months with the 100 μg dose, but this trend reversed 
(+1.6%) during the second 6 months. Overall, no signiﬁ  cant 
change was detected in the femoral neck. The bone turnover 
markers increased during the ﬁ  rst 6 months and maintained 
subsequently. The compliance was excellent (>95%), and 
treatment was generally safe and well tolerated. Dose-related 
incidences of transient hypercalcemia occurred, but only one 
patient (100 μg group) was withdrawn because of repeated 
hypercalcemia. No serious adverse events were reported. 
Pivotal study
The TOP (Treatment of osteoporosis with parathyroid 
hormone) study is an international, multi center, random-
ized (1:1), double-blind, placebo-controlled, parallel group, 
phase III study to compare the effects of 18 months of 
treatment with PTH or placebo on the incidence of new 
and/or worsened thoracic and lumbar vertebral fractures in 
postmenopausal women with osteoporosis receiving calcium 
Table 1 Clinical development of full length PTH
Study  Groups / n
A phase II double-blind, placebo-controlled, parallel group study to assess the   Placebo (n = 55)
safety and efﬁ  cacy of 3 doses of PTH (50, 75, and 100 μg) in the treatment of  PTH 50 μg (n = 52)
postmenopausal osteoporosis  PTH 75 μg (n = 55)
  PTH 100 μg (n = 55)
TOP.  An 18-month double-blind, placebo-controlled, phase III trial with a 12-month   Placebo (n = 1246)
analysis of the effect of PTH on fracture incidence in women with postmenopausal  PTH 100 μg (n = 1286) 
osteoporosis / patients were eligible to continue in OLES 
PaTH. PTH, and ALN in combination for the treatment of osteoporosis  Year 1:
  100 μg PTH +placebo (n = 119)
  Placebo + 10 mg ALN (n = 59)
  100 μg PTH + 10 mg ALN (n = 59)
POWER.  A phase III trial of PTH in women with low bone mass on stable  HRT + Placebo (n = 90)
estrogen replacement therapy  HRT + PTH 100 μg (n = 90)
PaTH. PTH and ALN in combination for the treatment of osteoporosis  Year 2:
  100 μg PTH + Placebo/10 mg ALN (n = 50)
  Placebo + 10 mg ALN /10 mg ALN (n = 55)
  100 μg PTH + 10 mg ALN/ 10 mg ALN  
  (n = 56)
  100 μg PTH/10 mg ALN (n = 53)
Rittmaster et al 2000.  Enhancement of bone mass in osteoporotic women with   10 mg ALN (n = 66)
PTH followed by ALN 
OLES.  An 18-month open-label extension study (OLES) of the safety and efﬁ  cacy  placebo/PTH 100 μg (n = 900)
of PTH, in women with postmenopausal osteoporosis who participated in TOP  PTH 100 μg/ PTH
Study. 24 month safety includes patients from TOP and OLE and not just OLE.  100 μg (n = 781)
Abbreviations: ALN, alendronate; HRT, hormone replacement therapy; OLES, open-label extension study; PTH, parathyroid hormone;TOP, treatment of osteoporosis with 
parathyroid hormone.Clinical Interventions in Aging 2007:2(1) 167
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and vitamin D3 supplements. Recently, as well as partial 
results (Recker et al 2004; Dempster et al 2005; Bogado 
et al 2005, 2006; Greenspan et al 2005; Miller and Greenspan 
2005; Silverman et al 2006), the peer-reviewed article has 
been published (Greenspan et al 2007).
To be eligible, participants had to be postmenopausal 
women, 45 years of age or older. If younger than 54 years, 
BMD had to be 3.0 standard deviations (SD) below 
mean peak bone mass or 2.5 SD with at least 1 prevalent 
vertebral fracture; if 55 years of age, BMD had to be 2.5 
SD below mean pike bone mass or 2.0 SD with at least 
1 prevalent vertebral fracture. Patients were randomized 
to receive either 100 μg PTH or placebo administered as a 
daily subcutaneous injection together with daily oral calcium 
(700 mg) and vitamin D3 (400 IU) supplements. To reduce 
the expected potential increases in serum and urine calcium 
concentrations after PTH administration, protocol-speciﬁ  ed 
management algorithms were predesigned. As a consequence 
of the ﬁ  ndings of osteosarcoma in a rat carcinogenicity study 
with teriparatide (fragment 1–34 of PTH) the study duration 
was reduced from 36 months to 18 months. 
The primary efﬁ  cacy endpoint was the incidence of new 
and/or worsened vertebral fractures (T4 to L4; by means of a 
semi-quantitative 4-point grading scale -0 to 3- corresponding 
to no reduction 20%, 20%–25%, 25%–40% or >40% reduc-
tion in anterior, middle, and/or posterior vertebral height in a 
blind fashion). Secondary efﬁ  cacy variables were incidences 
of vertebral fractures at month 12; hip and wrist; and other 
clinical fracture; changes in height; changes in BMD assessed 
by dual X-ray absorptiometry (DXA); bone mineral content 
(BMC) and bone mineral area (BMA) of the lumbar spine, 
proximal femur, whole body, and forearm; changes in cortical 
and trabecular bone compartments assessed by quantitative 
computed tomography (QCT) and peripheral QCT (pQCT) 
at lumbar spine, hip, forearm, distal femur, and central tibia 
(QCT substudy); and by bone histomorphometry at the iliac 
crest.
The study was powered to detect at least 90% of the 
times a difference between the treatment groups based on 
the assumption of a 60% reduction in fracture rate (30% in 
those with reduced dosage of PTH) and a fracture rate in the 
control group of 4.6%–5% (drop-out up to 20%). The needed 
number of patients was 2600. The study was conducted on 
an intention-to-treat- basis (including all patients randomised 
and who received 1 dose of double-blind study medication) 
by last observation carried forward methodology. 
From 10,749 subjects screened, 2679 subjects were 
randomized to receive either 100 μg PTH (1286 patients) or 
placebo (1246 patients) administered as a daily subcutaneous 
injection in the thigh or in the abdomen. The drop-out rate 
was greater than 30% (35.8% in the PTH group and 29.6% in 
the placebo group). Hypercalcemia (4 patients, 1 in placebo 
group [0.1] and 3 in PTH group [0.2]).and hypercalciuria (39 
patients, 15 [1.2%] in the placebo group and 24 [1.9%] in 
the PTH group) were more common in PTH-treated patients. 
Serious adverse events appeared in 39 subjects (1.5%); 22 
(1.8%) in the control group, and 17 (1.3%) in the PTH group. 
Twenty-three subjects (1.8%) in the placebo group and 20 
(1.6%) in the PTH group were noncompliant. 
The study population was comprised mostly of Caucasian 
(≈85%) and more than two thirds were younger than 74 years 
without prevalent vertebral fractures (placebo, 81.1%; PTH, 
81.6%). The majority of patients with prevalent vertebral 
fractures had, in fact, only one fracture (75%). The groups 
were comparable in terms of medical history, concomitant 
medications, weight, height, body mass index (BMI), preva-
lent vertebral fractures, and BMD (T-score; Lumbar spine: 
placebo –2.96, PTH –3.02) although the duration of bisphos-
phonate treatment was longer in the placebo group. 
At 18 months, there was approximately a 60% reduction 
in the risk of a new vertebral fracture in the PTH treated 
subjects (relative risk ratio: 0.42 [95% conﬁ  dence interval: 
0.24, 0.72], p = 0.001 in the ITT analysis) (Figure 1 and 2). 
Only one patient had more than one vertebral fracture and 
another had a worsening in the severity of a prevalent ver-
tebral fracture. The difference was not signiﬁ  cant at month 
12 (p = 0.290). The incidence of nonvertebral fractures did 
not show signiﬁ  cant differences (Placebo 73/1246 (5.86%), 
PTH 71/1286 (5.52%); p = 0.714) as occurred when non-
vertebral fractures were analysed according to localization 
(hip, wrist, other). 
PTH treatment induced a sustained increase in lumbar 
spine BMD (+6.5% at 18 months) whereas the BMD for 
the placebo group remained at or below baseline throughout 
the study (–0.3% at 18 months, p < 0.001) (Figure 3). The 
changes in BMD for femoral sites of measurement were simi-
lar except for an initial decrease in total hip BMD at 6 months 
followed by an increase at 12 and 18 months. One hundred 
and twenty-two patients were randomized in an ancillary 
study to assess changes in areal and volumetric cortical and 
trabecular bone volume evaluated by QCT and pQCT (62 in 
the placebo group and 60 in PTH group). Eighty-two patients 
(46 in the placebo group and 36 in the PTH group) completed 
the study. The volumetric trabecular BMD (vTbBMD) evalu-
ated in the lumbar vertebra L3 increased at month 3 and 12 
(+54.2%), after which declined to +38.3% at month 18. The Clinical Interventions in Aging 2007:2(1) 168
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Figure 1 New vertebral fractures in PTH and Pcb groups. TOP study. 
Abbreviations: Pcb, placebo; PTH, parathyroid hormone; TOP, treatment of osteoporosis with parathyroid hormone.
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changes in placebo group were +19% at month 3 with a 
subsequent decrease reaching baseline levels by month 18. 
The change in vTbBMD was signiﬁ  cant between PTH and 
placebo group at months 12 and 18.
The results of the bone biopsies from 16 women have 
been published as abstracts (Recker et al 2004; Dempster 
et al 2005) and as rapid original article (Fox et al 2005). 
Histomorphometricaly and in microcomputed tomography, 
trabecular bone showed increased bone volume (+48%), 
trabecular number (+21%) and bone formation rate, with 
reduced trabecular separation what improves connectivity 
and bone strength compared with placebo.
Open-label extension study
The women who had completed or had prematurely 
discontinued from TOP study were invited to enter in an 
OLES up to a maximum of 24 months. The primary objective 
was to evaluate the safety of continued administration of 
PTH during this period. Other objectives were to evaluate the 
changes in BMD (on ITT basis), the incidence of vertebral 
and nonvertebral clinical fractures, the changes in height, 
biochemical markers of bone turnover, and bone histomor-
phometry; quality of life, treatment satisfaction, assessments 
of dietary calcium intake, and immunological responses to 
PTH or Escherichia coli proteins were also measured as were 
the duration of the effect on BMD after discontinuation of 
PTH treatment. 
All patients received PTH given as a daily 100 μg subcu-
taneous injection (the patients whose study drug schedule had 
been reduced to one 100 μg injection every second day as a 
consequence of hypercalcemia or hypercalciuria received the 
same dose as they were following at the end of TOP study). 
All patients also received oral calcium (700 mg) and vita-
min D3 (400 IU) supplements unless they had discontinued 
calcium supplements in the TOP study. 
A total of 1681 patients received open-label PTH. Treat-
ment with PTH was discontinued when a patient reached a 
maximum total exposure of 24 months in TOP and OLES 
combined (Figure 3). Approximately 62% of the PTH/PTH 
treatment group completed 24 months of treatment, and 29% 
of the placebo/PTH group completed 18 months of treat-
ment. As expected, the baseline lumbar spine BMD for the 
OLES study was lower in the patients receiving placebo in 
the previous TOP study. Nevertheless, there were no differ-
ences between the treatment groups in baseline total hip and 
femoral neck T-score. The changes in lumbar spine BMD 
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during TOP and OLES studies are shown in Figure 3. The 
discontinuation of PTH treatment after 24 months of total 
exposure was associated to a decrease in BMD although the 
mean ﬁ  nal BMD was higher than the baseline value in the 
TOP study. In the subset of patients with available measure-
ments for the forearm BMD, a total loss of 6.1% was ob-
served. During the OLES study there were six new fractures 
(and one worsened fracture) in the placebo/PTH group and 
2 new fractures (and 4 worsened fractures) in those treated 
with PTH for 24 months. Nonvertebral clinical fractures were 
more common in the placebo/PTH group (29 patients) than 
in the PTH/PTH group (19 patients). 
Combination study and sequential study
The efficacy of PTH and alendronate (ALN) as mono-
therapy and in combination for the treatment of postmeno-
pausal osteoporosis was evaluated in a randomized, placebo-
controlled, 2 year, multicenter, double-blind, two periods 
factorial trial (Black et al 2003, 2005; Bauer et al 2006) The 
inclusion criteria were postmenopausal women (aged 55 to 
85 years), with BMD (T-score) < –2.5 at the lumbar spine or 
proximal femur or > –2.0 plus, at least, one additional risk 
factor for fracture. 238 women were randomized to receive 
during 12 months PTH 100 μg sc/daily, ALN 10 mg/day, or a 
combination of both (period I). in the second year of the study 
(period II), women in the original PTH group were randomly 
assigned to receive either ALN or matching placebo (Pcb) in 
a double-blind fashion , and women in the other two groups 
(combination group and ALN group) received open ALN. All 
participants received daily calcium (500 mg/day) and vitamin 
D (400 IU/day) supplements. During the ﬁ  rst year, the BMD 
at the spine increased in all the treatment groups (PTH, 6.3%; 
PTH + ALN, 6.1%; ALN, 4.6%), without signiﬁ  cant dif-
ferences in the increase between the PTH group and the 
combination-therapy group. Increases in BMD at the total hip 
were 1.9%, 0.3%, and 2.8% for the 3 groups, respectively. The 
volumetric density of trabecular bone at the spine increased 
more with PTH alone (about twice) than with combination 
therapy or alendronate alone. In the PTH group, the cortical 
volume at the hip increased, the volumetric density decreased, 
and the bone mineral content was unchanged, which is consis-
tent with the previously demonstrated actions of PTH (induc-
tion of new bone not fully mineralized and increased cortical 
porosity) (Dempster et al 2001; Misof et al 2003). Bone forma-
tion markers increased markedly in the PTH group, but not in 
the combination therapy group. Bone resorption decreased in 
the combination therapy group and the alendronate group. No 
relationship between baseline turnover and 1-year change in 
DXA and QCT BMD were detected in women treated with 
PTH alone. As expected in an anabolic therapy, bone turnover 
markers increased signiﬁ  cantly (Figure 4). The patients with 
greater increases in the short term (1 or 3 months) bone turn-
over, particularly in the formation marker PINP (an extension 
peptide derived from procollagen molecule), showed greater 
increases in areal BMD. The relationship was even greater 
with volumetric hip and spine BMD assessed by QCT, Each 
standard deviation increase in the 3-month change of PINP 
was associated with a 21% greater increase in QCT spine 
trabecular BMD (Bauer et al 2006). 
PTH for one year followed by one year of ALN treatment 
signiﬁ  cantly increased lumbar spine areal BMD by 12% 
(p < 0.001), compared with PTH + ALN, followed by ALN 
(8% and 11%), and ALN for two years (8% and 6%). The dif-
ference was particularly evident for BMD in trabecular bone 
at the spine on QCT (+31% in the PTH followed by ALN 
group compared with +14% in the PTH followed by placebo 
group, p < 0.001). During year two, compared with the PTH 
followed by Pcb group, patients in the PTH followed by ALN 
group showed a signiﬁ  cant further increase in lumbar spine 
and hip BMD (4.9% and 3.6%, respectively). Trabecular 
BMD at the spine and hip was also signiﬁ  cantly increased 
in this group. The PTH followed by Pcb group experienced 
a signiﬁ  cant decrease in lumbar spine BMD (–1.7%) without 
signiﬁ  cant changes in hip or radius BMD. Trabecular BMD 
was also signiﬁ  cantly decreased in the spine and hip. There 
was no signiﬁ  cant change in cortical volumetric BMD in 
either the PTH followed by ALN or PTH followed by Pcb 
groups. However, there were increases in both cortical BMD 
(4.6%) and cortical volume (4.4%) in the PTH followed by 
ALN group. (Black et al 2005). 
Other studies 
Rittmaster and colleagues (2000) enrolled a subset of the 
patients originally included in the dose ranking study in a 
1-year open-label extension of treatment with daily ALN 
(10 mg). 66/75 patients completed the study. There were 
statistically signiﬁ  cant differences for lumbar spinal BMD 
mean percentage change from baseline in favour of PTH 
75 μg and 100 μg followed by ALN compared with placebo 
followed by ALN. For the approved dose the increases in 
lumbar spine, hip, and total body BMD were 14.6%, 4.5%, 
and 6.1%, respectively. 
The POWER Study is a phase III, randomized, double-
blind, placebo-controlled, parallel-group, multicenter study, 
investigating the effect of PTH in women with low bone 
mass on stable estrogen replacement therapy. The results Clinical Interventions in Aging 2007:2(1) 171
PTH (1–84) in menopausal osteoporosis
are yet unpublished except in abstract form (Fogelman et al 
2005). Almost all patients discontinued the study treatment 
due to the published data on the risk of long-term hormone 
replacement therapy (HRT), and the study was terminated 
after all patients had received at least 18 months of study drug 
treatment. 180 patients were randomized (90 HRT; 90 HRT + 
PTH). The increase for lumbar spine BMD was signiﬁ  cantly 
greater in the PTH group compared with the placebo group 
(7.1% vs 1.1%, p < 0.001). For the femoral neck, there was 
also a statistically signiﬁ  cant increase in BMD (2.3% vs 
0.5%, p < 0.05). This study conﬁ  rmed the known effect of 
PTH on BMD and bone turnover parameters. 
Safety 
More than 3000 patients have received PTH in the main 
studies. Overall, PTH was well tolerated during the clinical 
trials. The most common treatment-related adverse events in 
the clinical trials and with greater incidence in PTH treated 
subjects were hypercalciuria (44% vs 21%), headache (29% 
vs 23%), hypercalcemia (27% vs 4%), nausea (22% vs 7%), 
and dizziness (12% vs 8%). Arthralgia and back pain had a 
similar incidence in PTH and placebo groups (22% and 20%, 
respectively). The proportion of patients with injection site-
related adverse events was also similar in both groups (Table 2). 
The most frequent serious adverse events in patients treated 
with PTH were hypercalcemia and events related to anemia. 
In most cases, hypercalcemia was transient and was re-
ported most frequently in the ﬁ  rst 3 months of treatment. It 
was managed during the clinical programme by monitoring 
laboratory values and the use of a prespeciﬁ  ed management 
algorithm involving withdrawal of calcium and vitamin D 
supplementation and, if necessary, PTH administration every 
other day. Considering the mechanism of action of PTH, 
its combined use with cardiac glucosides may predispose 
patients to digitalis toxicity if hypercalcemia develops. 
Renal calculi were more frequent in the PTH group than 
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Figure 4 Changes in bone turnover markers (formation: N-propeptide of type I collagen [PINP], bone speciﬁ  c alkaline phosphatase [BALP]; resorption: serum C-terminal 
telopeptide of type I collagen [sCTX]) during one year of therapy with PTH. TOP study.
Abbreviations: PTH, parathyroid hormone; TOP, treatment of osteoporosis with parathyroid hormone.Clinical Interventions in Aging 2007:2(1) 172
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in the placebo group. Caution is therefore recommended in 
patients treated with cardiac glucosides and those with ac-
tive or previous urolithiasis. A signiﬁ  cant elevation in uric 
acid was also detected in patients treated with PTH but the 
incidence of gout, arthralgia, and nephrolithiasis were similar 
in PTH and placebo groups. 
Discussion
The antifracture efﬁ  cacy of PTH has been documented in 
postmenopausal women with low BMD, with or without 
prevalent vertebral fractures. Patients treated with PTH had a 
61% relative risk reduction of a new vertebral fracture at month 
18 compared with patients in the placebo group although a 
reduction in the incidence of hip fracture—a secondary efﬁ  cacy 
endpoint in the pivotal study—has not been shown. 
BMD increased in PTH-treated patients. This increase 
could be considered as lower than expected in relation to 
teriparatide (Neer et al 2001), the other bone building treat-
ment, which shares N-terminal portion of the molecule pri-
marily responsible for the anabolic effects. Nevertheless, the 
efﬁ  cacy in reducing vertebral fractures was similar to other 
therapies with a similar mechanism of action.
As with other treatments for osteoporosis, although the 
relative risk reduction with PTH was similar in patients with 
Table 2 Adverse event experienced in the clinical development of full length PTH
 Very  Common  Uncommon
 common  (>1/100 and  (>1/1000 and
  (>1/10) <1/10)  <1/100)
  n (%)  n (%)  n (%)
Renal and urinary disorders
Hypercalcuria 39.3
Urine calcium/creatinine ratio increased    2.9
Urine calcium increased    2.2
Metabolism and nutrition disorders
Hypercalcemia 25.3
Blood calcium increased    3.1
Blood alkaline phosphatase increased      0.8
Anorexia     0.6
Blood uric acid increased      0.6
Gastrointestinal disorders
Nausea 13.5
Vomiting   2.5
Constipation   1.8
Dyspepsia   1.3
Diarrhea   1.0
Abdominal pain      0.8
Nervous system disorders
Headache   9.3
Dizziness   3.9
Dysgeusia     0.8
Parosmia     0.7
General disorders and administration site conditions
Injection site erythema    2.6
Fatigue   1.8
Asthenia   1.2
Injection site irritation      0.9
Musculoskeletal, connective tissue, and 
bone disorders
Muscle cramp    1.1
Pain in extremity    1.1
Back pain    1.0
Cardiac disorders
Palpitations   1.0
Infections and infestations
Inﬂ  uenza      0.5
Abbreviations: PTH, parathyroid hormone.Clinical Interventions in Aging 2007:2(1) 173
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and without prevalent fractures, the absolute risk reduction 
was much higher in patients with prevalent vertebral fractures. 
PTH has its greater antifracture efﬁ  cacy when administered in 
the abdomen and in high risk patients (BMD (T-score) at the 
lumbar spine  –3, prevalent vertebral fracture, advancing age, 
additional risk factors for osteoporosis), as stated by the Euro-
pean Medicines Agency in the European Public Assessment 
Report (EMEA 2006). On completion of PTH therapy (up to 
24 months), there is evidence that sequential treatment with 
ALN (by extrapolation, with bisphosphonates) was associated 
with a therapeutic beneﬁ  t in terms of increase in BMD. 
From the safety point of view, PTH was well tolerated 
during clinical trials. Nevertheless, patients treated with 
100 μg PTH more frequently reported hypercalciuria, 
hypercalcemia, and nausea: adverse events that were 
considered related to the treatment. No dose adjustment is 
necessary in patients with mild to moderate renal impairment 
(creatinine clearance 30 to 80 ml/min). There is no data 
available in patients with severe renal impairment and should 
therefore not be used in these patients. No dose adjustment 
is needed for patients with mild or moderate hepatic impair-
ment (total score of 7 to 9 on the Child-Pugh scale). PTH 
should therefore not be used in patients with severe hepatic 
impairment. Dose adjustment based upon age is not required. 
PTH is also contraindicated in patients with hypersensitivity 
to PTH or to any of the excipients, those who have previously 
received radiation therapy to the skeleton, with pre-existing 
hypercalcemia and other disturbances in the phosphocalcic 
metabolism, with metabolic bone diseases other than primary 
osteoporosis (including hyperparathyroidism and Paget’s 
disease of the bone) and with unexplained elevations of 
bone-speciﬁ  c alkaline phosphatase (EMEA 2006). 
At present time, several points need to be addressed. The 
potential effects of the C-terminal portion of the molecule and 
the effects on wrist and nonaxial fractures should be studied. 
The same is valid for the long-term safety (more than 2 years) 
and the possibility of repeated cycles of PTH followed by a 
bisphosphonate. More bone histomorphometry data are also 
needed. The investigation of the clinical proﬁ  le of patients 
suffering hypercalciuria and hypercalcemia, also the optimal 
pattern of use in this subset of patients have to be investigated. 
In the meantime, as stated in the product information by the 
European Medicines Agency, patients initiated on PTH therapy 
should be monitored at months 1, 3, and 6 for elevated levels 
of serum (20 to 24 hours after the administration of PTH) 
and/or urinary calcium. Monitoring beyond 6 months is not 
recommended for patients with normal total serum calcium at 
6 months. In patients with persistent elevated serum calcium 
(after excluding underlying disease. ie, hyperparathyroidism), 
calcium and vitamin D supplementation should be withdrawn 
and, if necessary, PTH should be administered as 100 μg every 
other day. If elevated calcium levels continue, PTH therapy 
should be stopped and the patient monitored.
In conclusion, full length PTH is the more recent incor-
poration into the therapeutic arsenal available for the therapy 
of osteoporosis. Full length PTH provides, together with 
signiﬁ  cant increases in BMD and bone turnover markers, an 
important reduction in the risk of new vertebral fractures in 
postmenopausal women with high risk osteoporosis.
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